Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.
2021
e15554Background: HER2 is an emerging treatment target for colorectal cancer (CRC). Previous phase 2 trials have demonstrated the promising antitumor activity of dual HER2 inhibition with trastuzum...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI